Effects of Chronic Smoking on Circulating Endothelial and Platelet-derived Microparticle

Status

Completed

Phases

Early Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00795249

Enrollment

100

Registered

2008-11-21

Start date

2008-11-30

Completion date

2010-11-30

Last updated

2011-06-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atherosclerosis

Brief summary

The investigators hypothesized that circulating EMP is a useful surrogate marker of early stage of endothelial damage. To determine the effects of chronic smoking on circulating EMP, from healthy volunteers who have habit of chronic smoking, peripheral blood is drawn at the time of flow-mediated dilatation (FMD) examination. Spot urine is also collected. Circulating EMPs are counted using flow-cytometry. After 2-week smoking cessation, the measurements were repeated.

Interventions

BEHAVIORALsmoking cessation

After baseline examination, the group is asked to quit smoking for 2 weeks.

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

SCREENING

Masking

NONE

Eligibility

Sex/Gender

MALE

Age

20 Years to 40 Years

Healthy volunteers

Yes

Inclusion criteria

* healthy individuals who have no coronary risk factors

Exclusion criteria

* hypertension * dyslipidemia * chronic kidney disease * liver dysfunction * obesity (BMI\>25.0) * cerebrovascular disease * other severe systemic diseases (cancer, inflammatory diseases, etc)

Design outcomes

Primary

Measure	Time frame
The number of circulating EMP	2 weeks

Secondary

Measure	Time frame
FMD	2 weeks

Countries

Japan

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026